First Header Logo Second Header Logo

Caio Max Rocha Lima

Concepts (292)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Pancreatic Neoplasms
33
2016
131
6.740
Why?
Antineoplastic Combined Chemotherapy Protocols
42
2017
401
6.590
Why?
Deoxycytidine
28
2014
63
3.600
Why?
Camptothecin
19
2014
48
3.020
Why?
Antineoplastic Agents
18
2016
547
2.160
Why?
Colorectal Neoplasms
13
2015
208
2.110
Why?
Lung Neoplasms
20
2015
388
1.830
Why?
Adenocarcinoma
12
2015
301
1.730
Why?
Neoplasms
12
2016
620
1.500
Why?
Taxoids
11
2017
48
1.340
Why?
Fluorouracil
12
2014
73
1.300
Why?
Antimetabolites, Antineoplastic
8
2010
48
1.250
Why?
Organoplatinum Compounds
8
2014
42
1.150
Why?
Carcinoma, Small Cell
8
2012
21
1.130
Why?
Carcinoma, Non-Small-Cell Lung
10
2006
94
1.130
Why?
Middle Aged
57
2017
10913
1.010
Why?
Humans
87
2017
29396
0.970
Why?
Aged
52
2017
9538
0.970
Why?
Antibodies, Monoclonal
10
2013
197
0.960
Why?
Paclitaxel
5
2013
51
0.900
Why?
Adult
44
2017
8503
0.860
Why?
Treatment Outcome
27
2017
3119
0.800
Why?
Male
56
2017
17930
0.780
Why?
Female
56
2017
18304
0.740
Why?
Salvage Therapy
4
2011
118
0.740
Why?
Neoadjuvant Therapy
7
2012
57
0.730
Why?
Colonic Neoplasms
3
2010
63
0.720
Why?
Chemotherapy, Adjuvant
8
2015
163
0.720
Why?
Neoplasm Metastasis
7
2014
199
0.710
Why?
Disease-Free Survival
11
2017
281
0.670
Why?
Gastrointestinal Stromal Tumors
5
2010
12
0.670
Why?
Antineoplastic Agents, Phytogenic
4
2005
38
0.670
Why?
Drug Administration Schedule
11
2016
247
0.650
Why?
Survival Analysis
11
2014
440
0.620
Why?
Cancer Vaccines
2
2014
21
0.600
Why?
Leucovorin
3
2012
20
0.600
Why?
Indoles
4
2016
58
0.590
Why?
Aged, 80 and over
24
2017
3733
0.590
Why?
Pyrroles
4
2016
55
0.580
Why?
Neoplasm Recurrence, Local
7
2017
337
0.580
Why?
Maximum Tolerated Dose
10
2014
56
0.580
Why?
Carcinoma, Pancreatic Ductal
2
2016
19
0.570
Why?
Carcinoma
3
2012
87
0.570
Why?
Neoplasm Staging
11
2014
438
0.560
Why?
Palliative Care
2
2010
47
0.550
Why?
Protein Kinase Inhibitors
3
2012
77
0.530
Why?
Endosonography
4
2011
56
0.530
Why?
Topotecan
4
2009
15
0.520
Why?
Angiogenesis Inhibitors
3
2016
34
0.510
Why?
Gastrins
1
2014
4
0.500
Why?
Stomach Neoplasms
3
2014
85
0.470
Why?
Survival Rate
15
2012
796
0.470
Why?
Esophageal Neoplasms
3
2011
33
0.460
Why?
Albumins
1
2013
39
0.450
Why?
Cell Cycle
1
2012
72
0.430
Why?
Antimitotic Agents
1
2012
2
0.420
Why?
Rectal Neoplasms
2
2009
14
0.420
Why?
Oligopeptides
1
2012
51
0.410
Why?
Clinical Trials as Topic
6
2008
299
0.410
Why?
Biopsy, Fine-Needle
4
2011
50
0.400
Why?
Piperidines
2
2012
125
0.400
Why?
Carcinoma, Squamous Cell
1
2012
143
0.390
Why?
Biliary Tract Neoplasms
2
2017
10
0.380
Why?
Cytoskeletal Proteins
1
2010
13
0.380
Why?
Infusions, Intravenous
5
2014
85
0.380
Why?
Drug Therapy
1
2010
16
0.360
Why?
Biopsy, Needle
2
2008
89
0.350
Why?
DNA Methylation
1
2010
131
0.350
Why?
Prognosis
9
2015
1367
0.350
Why?
Etoposide
3
2007
30
0.340
Why?
CA-19-9 Antigen
2
2013
5
0.330
Why?
Receptors, Vascular Endothelial Growth Factor
1
2008
20
0.320
Why?
Emphysematous Cholecystitis
1
2007
1
0.300
Why?
Drug Delivery Systems
1
2008
93
0.300
Why?
Quinazolines
4
2008
31
0.300
Why?
Ultrasonography, Interventional
2
2011
51
0.300
Why?
Carcinoma, Neuroendocrine
1
2007
13
0.300
Why?
Drug Resistance, Neoplasm
3
2012
90
0.280
Why?
Mediastinal Neoplasms
1
2006
13
0.280
Why?
Lymph Nodes
1
2006
92
0.270
Why?
Ablation Techniques
2
2016
24
0.270
Why?
Randomized Controlled Trials as Topic
8
2015
468
0.270
Why?
Electroporation
2
2016
14
0.260
Why?
Retrospective Studies
11
2016
3134
0.260
Why?
Combined Modality Therapy
7
2010
525
0.250
Why?
Disease Progression
5
2010
574
0.250
Why?
Coronary Vasospasm
1
2004
4
0.240
Why?
Diarrhea
3
2014
56
0.230
Why?
Hospitals, General
1
2013
4
0.230
Why?
Cancer Care Facilities
1
2013
6
0.230
Why?
Follow-Up Studies
7
2014
2118
0.230
Why?
Drug Synergism
3
2014
67
0.220
Why?
Liver Neoplasms
3
2014
163
0.220
Why?
Carboplatin
5
2007
40
0.220
Why?
Genetic Markers
1
2002
122
0.210
Why?
Tomography, X-Ray Computed
3
2016
871
0.180
Why?
Vomiting
2
2014
24
0.180
Why?
Nausea
2
2014
49
0.170
Why?
Pancreatic Diseases
2
2010
16
0.170
Why?
Protein-Tyrosine Kinases
2
2010
37
0.170
Why?
Gastrointestinal Neoplasms
2
2011
32
0.170
Why?
Clinical Trials, Phase III as Topic
4
2002
27
0.170
Why?
European Continental Ancestry Group
2
2014
1131
0.160
Why?
Piperazines
2
2010
56
0.160
Why?
Pyrimidines
2
2010
60
0.150
Why?
Pyridines
2
2008
78
0.150
Why?
Endothelins
1
2017
4
0.150
Why?
Brain Neoplasms
1
2003
588
0.150
Why?
Radiography, Interventional
1
2016
35
0.140
Why?
Young Adult
4
2014
2422
0.140
Why?
Epothilones
1
2016
3
0.140
Why?
Tubulin Modulators
1
2016
10
0.140
Why?
African Americans
2
2014
1373
0.140
Why?
Pancreatectomy
2
2012
29
0.130
Why?
Clinical Trials, Phase II as Topic
4
2006
18
0.130
Why?
Splenic Artery
1
2015
12
0.130
Why?
Thrombocytopenia
1
2015
32
0.130
Why?
Breast Neoplasms
3
2012
673
0.130
Why?
Neutropenia
1
2014
23
0.120
Why?
Electrochemotherapy
1
2014
3
0.120
Why?
Sensitivity and Specificity
4
2011
533
0.120
Why?
Embolization, Therapeutic
1
2015
79
0.120
Why?
Injections, Intramuscular
1
2014
42
0.120
Why?
Time Factors
4
2016
2010
0.120
Why?
Peptide Fragments
1
2017
423
0.120
Why?
Perception
1
2014
92
0.120
Why?
Quality of Life
3
2004
825
0.120
Why?
Pancreas
2
2011
79
0.120
Why?
Receptor, erbB-2
1
2014
45
0.120
Why?
Immunohistochemistry
2
2012
520
0.120
Why?
Arsenic
1
2013
5
0.110
Why?
Hematologic Diseases
2
2004
23
0.110
Why?
Attitude to Health
1
2014
148
0.110
Why?
Proto-Oncogene Proteins c-kit
2
2010
24
0.110
Why?
Prospective Studies
7
2014
2040
0.110
Why?
Trisaccharides
1
2012
1
0.110
Why?
Deoxyglucose
1
2012
16
0.110
Why?
Immunotherapy, Active
1
2012
6
0.110
Why?
Cyclin-Dependent Kinases
1
2012
10
0.110
Why?
Pancreaticoduodenectomy
1
2012
21
0.110
Why?
Drug Design
1
2012
44
0.110
Why?
Benzamides
2
2010
54
0.110
Why?
Clinical Trials, Phase I as Topic
3
2004
14
0.110
Why?
Adolescent
4
2014
3273
0.110
Why?
Catheter Ablation
1
2012
62
0.110
Why?
Environmental Exposure
1
2013
87
0.110
Why?
Algorithms
2
2012
467
0.100
Why?
Triazines
1
2011
3
0.100
Why?
Boronic Acids
2
2008
7
0.100
Why?
Pyrazines
2
2008
11
0.100
Why?
Alanine
1
2011
27
0.100
Why?
Cell Line, Tumor
2
2010
684
0.100
Why?
Celiac Plexus
1
2011
3
0.100
Why?
Diagnosis, Differential
3
2010
493
0.100
Why?
Family
1
2011
105
0.100
Why?
Metalloproteases
1
2010
3
0.100
Why?
Diagnostic Imaging
2
2008
88
0.100
Why?
Abdominal Pain
1
2011
40
0.100
Why?
CARD Signaling Adaptor Proteins
1
2010
4
0.100
Why?
Cyclooxygenase 2 Inhibitors
1
2010
15
0.100
Why?
Azacitidine
1
2010
28
0.090
Why?
Gene Silencing
1
2010
49
0.090
Why?
Proto-Oncogene Proteins c-akt
1
2010
69
0.090
Why?
Mutation
2
2010
469
0.090
Why?
Caregivers
1
2011
95
0.090
Why?
Vascular Endothelial Growth Factor A
1
2010
104
0.090
Why?
Transfection
1
2010
192
0.090
Why?
Biliary Tract Diseases
1
2010
8
0.090
Why?
Cisplatin
3
2011
69
0.090
Why?
Cholangiopancreatography, Endoscopic Retrograde
1
2010
31
0.090
Why?
Promoter Regions, Genetic
1
2010
213
0.090
Why?
Radiation Tolerance
1
2009
22
0.090
Why?
Proteins
1
2010
140
0.090
Why?
Models, Genetic
1
2009
95
0.090
Why?
Lymphatic Metastasis
2
2007
156
0.090
Why?
Depression
1
2011
386
0.080
Why?
Benzenesulfonates
1
2008
3
0.080
Why?
Endoscopy
1
2008
40
0.080
Why?
Phenylurea Compounds
1
2008
11
0.080
Why?
Niacinamide
1
2008
8
0.080
Why?
Gene Expression
1
2009
334
0.080
Why?
DNA Topoisomerases, Type I
2
2006
9
0.080
Why?
Head and Neck Neoplasms
1
2009
118
0.080
Why?
Patient Care Team
1
2008
124
0.080
Why?
Administration, Oral
2
2007
169
0.080
Why?
Cholecystostomy
1
2007
1
0.080
Why?
Hyperbilirubinemia
1
2007
2
0.080
Why?
Leukocytosis
1
2007
8
0.080
Why?
Phosphorylcholine
1
2007
5
0.070
Why?
Probability
1
2007
150
0.070
Why?
Radiography
2
2012
354
0.070
Why?
Risk Factors
2
2014
3588
0.070
Why?
Proportional Hazards Models
3
2016
711
0.070
Why?
Acute Disease
1
2007
239
0.070
Why?
Sarcoma
1
2007
56
0.070
Why?
Feasibility Studies
1
2007
268
0.070
Why?
Equipment Design
1
2006
167
0.070
Why?
Models, Statistical
1
2006
164
0.070
Why?
Alkyl and Aryl Transferases
1
2004
2
0.060
Why?
Thalidomide
1
2005
29
0.060
Why?
Quinolones
1
2004
6
0.060
Why?
Electrocardiography
2
2012
568
0.060
Why?
Anti-Bacterial Agents
1
2007
286
0.060
Why?
Enterocolitis, Neutropenic
1
2004
1
0.060
Why?
Dose-Response Relationship, Drug
4
2010
641
0.060
Why?
Patient Selection
2
2007
257
0.060
Why?
Aniline Compounds
1
2014
25
0.060
Why?
Proto-Oncogene Proteins c-bcl-2
1
2014
31
0.060
Why?
Imidazoles
1
2004
104
0.060
Why?
Signal Transduction
1
2008
669
0.060
Why?
Lymphocytes
1
2004
55
0.060
Why?
Sulfonamides
1
2014
65
0.060
Why?
Enzyme Inhibitors
1
2004
162
0.060
Why?
Hospitals, Voluntary
1
2013
2
0.060
Why?
Epidermal Growth Factor
1
2003
21
0.060
Why?
Blood-Brain Barrier
1
2003
43
0.060
Why?
SEER Program
3
2007
33
0.050
Why?
Poverty
1
2013
99
0.050
Why?
Survival
1
2002
13
0.050
Why?
Neoplasms, Unknown Primary
1
2002
5
0.050
Why?
Safety
1
2002
73
0.050
Why?
Age Distribution
1
2002
199
0.050
Why?
Stress, Psychological
2
2014
210
0.050
Why?
Lymphoma, Non-Hodgkin
1
2001
20
0.050
Why?
Hematologic Neoplasms
1
2001
28
0.050
Why?
Granulocyte Colony-Stimulating Factor
1
2001
21
0.050
Why?
Longitudinal Studies
2
2014
725
0.050
Why?
Multicenter Studies as Topic
1
2000
93
0.050
Why?
Florida
2
2013
35
0.050
Why?
Area Under Curve
2
2010
85
0.040
Why?
Tumor Burden
1
2016
60
0.040
Why?
Reproducibility of Results
2
2010
727
0.040
Why?
Incidence
2
2013
1124
0.040
Why?
Neovascularization, Pathologic
1
2016
81
0.030
Why?
Registries
2
2007
280
0.030
Why?
Georgia
1
2014
13
0.030
Why?
Family Relations
1
2014
22
0.030
Why?
Epirubicin
1
2014
1
0.030
Why?
Water Supply
1
2013
10
0.030
Why?
Positron-Emission Tomography
1
2014
172
0.030
Why?
Antigens, Neoplasm
1
2013
44
0.030
Why?
Cluster Analysis
1
2013
129
0.030
Why?
Receptor, IGF Type 1
1
2012
7
0.030
Why?
Placebos
1
2012
61
0.030
Why?
Rare Diseases
1
2012
20
0.030
Why?
Neoplasm Proteins
1
2013
141
0.030
Why?
Esophagogastric Junction
1
2011
7
0.030
Why?
Aneuploidy
1
2011
8
0.030
Why?
Chromosomes, Human, Pair 17
1
2011
11
0.030
Why?
Chromosomes, Human, Pair 9
1
2011
13
0.030
Why?
Chromosomes, Human, Pair 7
1
2011
15
0.030
Why?
In Situ Hybridization, Fluorescence
1
2011
38
0.030
Why?
Sequence Deletion
1
2011
36
0.030
Why?
Chromosomes, Human, Pair 3
1
2011
28
0.030
Why?
Vascular Endothelial Growth Factor Receptor-2
1
2011
22
0.020
Why?
Tissue Distribution
1
2011
55
0.020
Why?
Autonomic Nerve Block
1
2011
9
0.020
Why?
Logistic Models
1
2013
729
0.020
Why?
Analgesia
1
2011
33
0.020
Why?
Social Support
1
2011
165
0.020
Why?
Drug Therapy, Combination
1
2011
273
0.020
Why?
Antigens, Tumor-Associated, Carbohydrate
1
2010
3
0.020
Why?
Half-Life
1
2010
22
0.020
Why?
Biliary Tract
1
2010
7
0.020
Why?
Blood Glucose
1
2012
469
0.020
Why?
Pain Measurement
1
2011
365
0.020
Why?
Oligonucleotide Array Sequence Analysis
1
2009
155
0.020
Why?
United States
2
2007
3673
0.020
Why?
Sample Size
1
2008
37
0.020
Why?
Linear Models
1
2009
427
0.020
Why?
Muscle Neoplasms
1
2007
8
0.020
Why?
Endoscopy, Gastrointestinal
1
2007
26
0.020
Why?
Muscle, Smooth
1
2007
74
0.020
Why?
Antiemetics
1
2007
5
0.020
Why?
DNA Topoisomerases, Type II
1
2006
4
0.020
Why?
Bone Neoplasms
1
2007
105
0.020
Why?
Population Surveillance
1
2007
119
0.020
Why?
Case-Control Studies
1
2008
861
0.020
Why?
Multivariate Analysis
1
2007
638
0.020
Why?
Farnesyltranstransferase
1
2004
2
0.020
Why?
Models, Chemical
1
2004
30
0.020
Why?
Inhibitory Concentration 50
1
2004
23
0.020
Why?
Leukocytes, Mononuclear
1
2004
50
0.020
Why?
Flavonoids
1
2004
18
0.020
Why?
Peritoneal Neoplasms
1
2007
241
0.020
Why?
Fatal Outcome
1
2004
78
0.020
Why?
Severity of Illness Index
1
2007
864
0.010
Why?
Cohort Studies
1
2007
1699
0.010
Why?
Vinblastine
1
2000
6
0.010
Why?
Child
1
2007
2227
0.010
Why?
Remission Induction
1
2000
78
0.010
Why?
Tumor Cells, Cultured
1
1999
159
0.010
Why?
Rocha Lima's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (292)
Explore
_
Similar People (48)
Explore
_
Same Department Expand Description
Explore
_